STEVENSON, Md., Dec. 20, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of TerraVia Holdings, Inc. (Nasdaq:TVIA) (“TerraVia” or the “Company”) securities during the period between August 8, 2016 through November 7, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until January 17, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in TerraVia securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that TerraVia’s products caused gastrointestinal distress, such as nausea and vomiting.
According to the complaint, following a November 7, 2016 Bloomberg report that TerraVia sent a letter to a distributor in July warning that TerraVia had received reports showing that algal protein can cause gastrointestinal distress, the value of TerraVia shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in TerraVia securities purchased on or after August 8, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
First Western Ship Transits Strait of Hormuz Since Iran War Began
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 



